JPWO2019023564A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019023564A5 JPWO2019023564A5 JP2020503739A JP2020503739A JPWO2019023564A5 JP WO2019023564 A5 JPWO2019023564 A5 JP WO2019023564A5 JP 2020503739 A JP2020503739 A JP 2020503739A JP 2020503739 A JP2020503739 A JP 2020503739A JP WO2019023564 A5 JPWO2019023564 A5 JP WO2019023564A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- aqueous solution
- set forth
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007864 aqueous solution Substances 0.000 claims 23
- 102000004965 antibodies Human genes 0.000 claims 21
- 108090001123 antibodies Proteins 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 239000000243 solution Substances 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 5
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 5
- 239000008363 phosphate buffer Substances 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 102100014838 FCGRT Human genes 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 229940068968 Polysorbate 80 Drugs 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229960001230 Asparagine Drugs 0.000 claims 1
- 101710003435 FCGRT Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (17)
- 安定的水溶液であって、
（ａ）約１００ｍｇ／ｍＬの濃度の抗Ｃ５抗体であって、配列番号１９に記載されるアミノ酸配列を含む重鎖ＣＤＲ１、配列番号１８に記載されるアミノ酸配列を含む重鎖ＣＤＲ２、配列番号３に記載されるアミノ酸配列を含む重鎖ＣＤＲ３、配列番号４に記載されるアミノ酸配列を含む軽鎖ＣＤＲ１、配列番号５に記載されるアミノ酸配列を含む軽鎖ＣＤＲ２、および配列番号６に記載されるアミノ酸配列を含む軽鎖ＣＤＲ３、を含む抗Ｃ５抗体、
（ｂ）約５０ｍＭのリン酸緩衝液、
（ｃ）約５％のスクロース、および
（ｄ）約２５ｍＭのアルギニンを含む、安定的水溶液。 - 安定的水溶液であって、
（ａ）抗Ｃ５抗体であって、配列番号１９に記載されるアミノ酸配列を含む重鎖ＣＤＲ１、配列番号１８に記載されるアミノ酸配列を含む重鎖ＣＤＲ２、配列番号３に記載されるアミノ酸配列を含む重鎖ＣＤＲ３、配列番号４に記載されるアミノ酸配列を含む軽鎖ＣＤＲ１、配列番号５に記載されるアミノ酸配列を含む軽鎖ＣＤＲ２、および配列番号６に記載されるアミノ酸配列を含む軽鎖ＣＤＲ３、を含む抗Ｃ５抗体、
（ｂ）約５０ｍＭのリン酸緩衝液、
（ｃ）約５％のスクロース、
（ｄ）約０．０５％のポリソルベート８０、および
（ｅ）約２５ｍＭのアルギニンを含む、安定的水溶液。 - 界面活性剤をさらに含む、請求項１に記載の安定的水溶液。
- 前記界面活性剤が、約０．０５％のポリソルベート８０である、請求項３に記載の安定的水溶液。
- 前記抗Ｃ５抗体が、約１００ｍｇ／ｍＬの濃度である、請求項２に記載の安定的水溶液。
- 前記抗Ｃ５抗体が、ヒト新生児型Ｆｃ受容体（ＦｃＲｎ）に結合するバリアントヒトＦｃ定常領域をさらに含み、前記バリアントヒトＦｃ ＣＨ３定常領域は、各々ＥＵナンバリングで、天然型ヒトＩｇＧ Ｆｃ定常領域のメチオニン４２８およびアスパラギン４３４に対応する残基に、Ｍｅｔ－４２９－ＬｅｕおよびＡｓｎ－４３５－Ｓｅｒの置換を含む、請求項１または２に記載の安定的水溶液。
- 前記抗Ｃ５抗体が、配列番号１２に記載される重鎖可変領域と、配列番号８に記載される軽鎖可変領域を含む、請求項１または２に記載の安定的水溶液。
- 前記抗Ｃ５抗体が、配列番号１３に記載される重鎖定常領域を含む、請求項１または２に記載の安定的水溶液。
- 前記抗Ｃ５抗体が、配列番号１４に記載されるアミノ酸配列を含む重鎖ポリペプチドと、配列番号１１に記載されるアミノ酸配列を含む軽鎖ポリペプチドを含む、請求項１または２に記載の安定的水溶液。
- 前記抗Ｃ５抗体が、ＡＬＸＮ１２１０（ラブリズマブ）である、請求項１または２に記載の安定的水溶液。
- 前記溶液のｐＨが、７．２～７．６である、請求項１または２に記載の安定的水溶液。
- 前記溶液のｐＨが、７．４である、請求項１１に記載の安定的水溶液。
- 前記溶液が、滅菌されている、請求項１または２に記載の安定的水溶液。
- （ａ）前記抗Ｃ５抗体が、少なくとも６カ月間、２℃～８℃で保存中、ＳＥＣ－ＨＰＬＣにより決定されたときに少なくとも９７％の単量体を維持している；
（ｂ）前記溶液中、前記抗Ｃ５抗体の３％未満が、ＳＥＣ－ＨＰＬＣにより決定されたときに凝集している；および／または
（ｃ）少なくとも６カ月間、２℃～８℃で保存中、前記抗Ｃ５抗体が、保存前の前記抗Ｃ５抗体と比較して、そのＣ５結合活性を少なくとも９０％維持している、
請求項１または２に記載の安定的水溶液。 - 前記溶液が、皮下投与または静脈内投与に適している、請求項１または２に記載の安定的水溶液。
- １００ｍｇ／ｍＬの濃度の、配列番号２３に記載されるアミノ酸配列を含む重鎖ＣＤＲ１、配列番号１９に記載されるアミノ酸配列を含む重鎖ＣＤＲ２、配列番号３に記載されるアミノ酸配列を含む重鎖ＣＤＲ３、配列番号４に記載されるアミノ酸配列を含む軽鎖ＣＤＲ１、配列番号５に記載されるアミノ酸配列を含む軽鎖ＣＤＲ２、および配列番号６に記載されるアミノ酸配列を含む軽鎖ＣＤＲ３を含む抗Ｃ５抗体、５０ｍＭのリン酸緩衝剤、５％のスクロース、および２５ｍＭのアルギニンを含む、安定的な濃縮抗体溶液を作製する方法であって、
ｉ）前記抗Ｃ５抗体を含む第一の水溶液を提供することであって、前記第一の水溶液は、第一の製剤を有し、１０ｍｇ／ｍＬ以下の前記抗Ｃ５抗体を含む、提供することと、
ｉｉ）前記第一の水溶液に、ｐＨ７．４で５０ｍＭのリン酸緩衝剤、５％のスクロース、および２５ｍＭのアルギニンを含む製剤への透析ろ過を行い、それにより第二の水溶液を作製することであって、前記第二の水溶液は、前記透析ろ過の結果として第二の製剤を有する、行うことと、
ｉｉｉ）前記第二の水溶液を濃縮し、１００ｍｇ／ｍＬの抗Ｃ５抗体、５０ｍＭのリン酸緩衝剤、５％のスクロースおよび２５ｍＭのアルギニンを含む安定的な濃縮抗体溶液を作製することと、を含む、方法。 - 請求項１に記載の前記安定的水溶液を含む治療用キット。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022083775A JP7277649B2 (ja) | 2017-07-27 | 2022-05-23 | 高濃度抗ｃ５抗体製剤 |
| JP2023076675A JP2023090876A (ja) | 2017-07-27 | 2023-05-08 | 高濃度抗ｃ５抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537741P | 2017-07-27 | 2017-07-27 | |
| US62/537,741 | 2017-07-27 | ||
| PCT/US2018/044071 WO2019023564A1 (en) | 2017-07-27 | 2018-07-27 | ANTI-C5 ANTIBODY FORMULATIONS WITH HIGH CONCENTRATION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022083775A Division JP7277649B2 (ja) | 2017-07-27 | 2022-05-23 | 高濃度抗ｃ５抗体製剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020528894A JP2020528894A (ja) | 2020-10-01 |
| JP2020528894A5 JP2020528894A5 (ja) | 2021-09-09 |
| JPWO2019023564A5 true JPWO2019023564A5 (ja) | 2022-03-15 |
| JP7079844B2 JP7079844B2 (ja) | 2022-06-02 |
Family
ID=63209670
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503739A Active JP7079844B2 (ja) | 2017-07-27 | 2018-07-27 | 高濃度抗ｃ５抗体製剤 |
| JP2022083775A Active JP7277649B2 (ja) | 2017-07-27 | 2022-05-23 | 高濃度抗ｃ５抗体製剤 |
| JP2023076675A Pending JP2023090876A (ja) | 2017-07-27 | 2023-05-08 | 高濃度抗ｃ５抗体製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022083775A Active JP7277649B2 (ja) | 2017-07-27 | 2022-05-23 | 高濃度抗ｃ５抗体製剤 |
| JP2023076675A Pending JP2023090876A (ja) | 2017-07-27 | 2023-05-08 | 高濃度抗ｃ５抗体製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11365241B2 (ja) |
| EP (2) | EP4218813A3 (ja) |
| JP (3) | JP7079844B2 (ja) |
| KR (2) | KR20230066126A (ja) |
| CN (2) | CN111315411B (ja) |
| AU (2) | AU2018306612C1 (ja) |
| BR (1) | BR112020001703B1 (ja) |
| CA (1) | CA3069756A1 (ja) |
| CO (1) | CO2020001960A2 (ja) |
| DK (1) | DK3658184T3 (ja) |
| ES (1) | ES2965486T3 (ja) |
| FI (1) | FI3658184T3 (ja) |
| HU (1) | HUE064436T2 (ja) |
| LT (1) | LT3658184T (ja) |
| MX (2) | MX2020001052A (ja) |
| PL (1) | PL3658184T3 (ja) |
| PT (1) | PT3658184T (ja) |
| SI (1) | SI3658184T1 (ja) |
| WO (1) | WO2019023564A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3118282A1 (en) * | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| JP2022520107A (ja) * | 2019-02-14 | 2022-03-28 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
| JP2022544589A (ja) * | 2019-08-16 | 2022-10-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高濃度抗ｃ５製剤 |
| WO2021067526A1 (en) * | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
| US20230002482A1 (en) * | 2019-11-08 | 2023-01-05 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
| EP4149421A1 (en) * | 2020-05-15 | 2023-03-22 | F. Hoffmann-La Roche AG | Prevention of visible particle formation in parenteral protein solutions |
| MX2023003256A (es) * | 2020-09-21 | 2023-04-11 | Alexion Pharma Inc | Dosificacion y administracion de anticuerpos anti-c5 para tratar la glomerulonefritis (gn) mediada por c5, incluyendo la nefritis lupica (nl) y/o la nefropatia por iga (niga). |
| KR20230134533A (ko) * | 2021-01-22 | 2023-09-21 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-c5 항체를 이용한 보체 매개 혈전성 미세혈관병증의치료 방법 |
| TW202404632A (zh) * | 2022-04-04 | 2024-02-01 | 瑞士商赫孚孟拉羅股份公司 | 用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案 |
| WO2024072798A1 (en) * | 2022-09-28 | 2024-04-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for preventing or minimizing cardiac surgery associated acute kidney injury (csa-aki) and/or subsequent major adverse kidney events (make) in patients with chronic kidney disease |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| AU656544B2 (en) | 1990-10-31 | 1995-02-09 | Brigham And Women's Hospital | Genetic modification of endothelial cells |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2137667A1 (en) | 1992-07-23 | 1994-02-03 | Todd A. Berg | Shaped abrasive particles and method of making same |
| PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| IT1265573B1 (it) | 1993-09-17 | 1996-11-22 | Zanussi Grandi Impianti Spa | Forno di cottura di alimenti con porta perfezionata |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| PT748213E (pt) | 1994-03-07 | 2004-08-31 | Nektar Therapeutics | Metodos e composicoes para administracao pulmonar de insulina |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US6001329A (en) | 1996-05-06 | 1999-12-14 | Uab Research Foundation | Radiolabeled fusion toxins for cancer therapy |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| GB9626960D0 (en) | 1996-12-27 | 1997-02-12 | Glaxo Group Ltd | Valve for aerosol container |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU7467898A (en) | 1997-04-21 | 1998-11-13 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
| US7112341B1 (en) | 1999-04-13 | 2006-09-26 | Nektar Therapeutics | Pulmonary administration of dry powder formulations for treating infertility |
| WO2000061178A1 (en) | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| GB9910975D0 (en) | 1999-05-13 | 1999-07-14 | Univ Strathclyde | Rapid dehydration of proteins |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| ATE404140T1 (de) | 2000-08-30 | 2008-08-15 | Univ Johns Hopkins | Vorrichtung zur intraokularen wirkstoffverabreichung |
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| CA2460063C (en) | 2001-09-12 | 2010-07-20 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| EP1511861A4 (en) | 2002-06-12 | 2007-12-05 | Genencor Int | METHODS AND BINDING COMPOSITIONS DEPENDENT FROM THE MEDIUM OF A TARGET AGENT TO A TARGET |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| FR2849436B1 (fr) | 2002-12-27 | 2007-01-05 | Patrick Frayssinet | Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro |
| US20060167435A1 (en) | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
| PL2335725T3 (pl) | 2003-04-04 | 2017-04-28 | Genentech, Inc. | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
| CA2534077A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| GB0416328D0 (en) | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
| WO2006031994A2 (en) | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2845865A1 (en) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Fc variants with altered binding to FcRn |
| US20060234303A1 (en) | 2005-03-03 | 2006-10-19 | Xencor, Inc. | Methods for the design of libraries of protein variants |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| EP1962907A2 (en) | 2005-12-21 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Protein formulations with reduced viscosity and uses thereof |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| US8037880B2 (en) | 2006-04-07 | 2011-10-18 | The University Of Western Ontario | Dry powder inhaler |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| AU2007313300A1 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molecules with reduced half-lives, compositions and uses thereof |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| EP2173380A4 (en) | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
| SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
| HUE024903T2 (en) | 2007-12-26 | 2016-02-29 | Xencor Inc | FC variants with modified binding to FCRN |
| CN107488228A (zh) | 2008-04-11 | 2017-12-19 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
| RU2536937C2 (ru) | 2008-10-14 | 2014-12-27 | Дженентек, Инк. | Варианты иммуноглобулина и их применения |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| SG10201507722QA (en) | 2010-03-11 | 2015-10-29 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
| WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US20190135903A1 (en) * | 2015-03-31 | 2019-05-09 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
| WO2017057644A1 (ja) | 2015-09-30 | 2017-04-06 | 持田製薬株式会社 | 高濃度抗体含有液体製剤 |
| CA3027487A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| US20230002482A1 (en) | 2019-11-08 | 2023-01-05 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
-
2018
- 2018-07-27 DK DK18755604.8T patent/DK3658184T3/da active
- 2018-07-27 LT LTEPPCT/US2018/044071T patent/LT3658184T/lt unknown
- 2018-07-27 CN CN201880048000.5A patent/CN111315411B/zh active Active
- 2018-07-27 KR KR1020237014547A patent/KR20230066126A/ko active Application Filing
- 2018-07-27 PL PL18755604.8T patent/PL3658184T3/pl unknown
- 2018-07-27 FI FIEP18755604.8T patent/FI3658184T3/fi active
- 2018-07-27 US US16/633,930 patent/US11365241B2/en active Active
- 2018-07-27 PT PT187556048T patent/PT3658184T/pt unknown
- 2018-07-27 EP EP23152642.7A patent/EP4218813A3/en active Pending
- 2018-07-27 MX MX2020001052A patent/MX2020001052A/es unknown
- 2018-07-27 EP EP18755604.8A patent/EP3658184B1/en active Active
- 2018-07-27 ES ES18755604T patent/ES2965486T3/es active Active
- 2018-07-27 SI SI201831024T patent/SI3658184T1/sl unknown
- 2018-07-27 AU AU2018306612A patent/AU2018306612C1/en active Active
- 2018-07-27 HU HUE18755604A patent/HUE064436T2/hu unknown
- 2018-07-27 WO PCT/US2018/044071 patent/WO2019023564A1/en active Application Filing
- 2018-07-27 BR BR112020001703-5A patent/BR112020001703B1/pt active IP Right Grant
- 2018-07-27 KR KR1020207003840A patent/KR102576012B1/ko active IP Right Grant
- 2018-07-27 CA CA3069756A patent/CA3069756A1/en active Pending
- 2018-07-27 CN CN202310099760.1A patent/CN116271012A/zh active Pending
- 2018-07-27 JP JP2020503739A patent/JP7079844B2/ja active Active
-
2020
- 2020-01-27 MX MX2022005990A patent/MX2022005990A/es unknown
- 2020-02-24 CO CONC2020/0001960A patent/CO2020001960A2/es unknown
-
2022
- 2022-05-06 US US17/738,131 patent/US20230106734A1/en active Pending
- 2022-05-23 JP JP2022083775A patent/JP7277649B2/ja active Active
- 2022-11-29 AU AU2022279414A patent/AU2022279414A1/en active Pending
- 2022-12-21 US US18/086,031 patent/US20230257456A1/en active Pending
-
2023
- 2023-05-08 JP JP2023076675A patent/JP2023090876A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| CN110418803B (zh) | 抗rsv单克隆抗体配制品 | |
| JP7293122B2 (ja) | 補体が媒介する疾患および障害を処置するための方法 | |
| JP6007316B2 (ja) | 抗体製剤 | |
| US11274148B2 (en) | Biopharmaceutical compositions | |
| JP2020528894A5 (ja) | ||
| JP2014524748A5 (ja) | ||
| JP2016534052A5 (ja) | ||
| US9457089B2 (en) | Highly concentrated aqueous protein solution with reduced viscosity | |
| WO2020094122A1 (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| RU2015130100A (ru) | TNF-альфа антиген-связывающие белки | |
| US20180142010A1 (en) | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant | |
| ES2699078T3 (es) | Proteínas de unión a antigeno específicas para componente amiloide sérico P | |
| JPWO2019023564A5 (ja) | ||
| JP2020158505A5 (ja) | ||
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| WO2018184593A1 (zh) | 用于治疗乙肝感染及相关疾病的抗体 | |
| JP2023501377A (ja) | 高濃度抗ｃ５抗体配合物 | |
| KR20230058432A (ko) | 약제학적 제형 | |
| JP2023535384A (ja) | 抗ｐｄ－１抗体医薬組成物及びその用途 | |
| WO2022117060A1 (zh) | 一种含抗结缔组织生长因子抗体的药物组合物 | |
| TW202323281A (zh) | 間皮素結合蛋白及其用途 | |
| RU2745814C1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение | |
| TW202233674A (zh) | 用於調節δγ鏈介導之免疫的組成物及方法 | |
| US20230406942A1 (en) | Igf1r antibodies |